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Eosinophilic granulomatosis with polyangiitis (EGPA) is a multisystemic disorder, belong-
ing to the small vessel anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis,
defined as an eosinophil-rich and necrotizing granulomatous inflammation often involving
the respiratory tract, and necrotizing vasculitis predominantly affecting small to medium-
sized vessels, associated with asthma and eosinophilia. EGPA pathogenesis is not well
known: HLA-DRB1*04 and *07, HLA-DRB4 and IL10.2 haplotype of the IL-10 promoter
gene are the most studied genetic determinants. Among the acquired pathogenetic fac-
tors, the exposure to different allergens, infections, vaccinations, drugs, and silica exposure
have been involved. Eosinophils are the most characteristic cells in EGPA and different
studies have demonstrated their role as effector and immunoregulatory cells. EGPA is
considered as a disease with a prevalent activation of theTh-2 cellular-mediated inflamma-
tory response and also humoral immunity plays an important role. A link between B and
T inflammatory responses may explain different disease features. EGPA typically develops
into three sequential phases: the allergic phase, distinguished by the occurrence of asthma,
allergic rhinitis, and sinusitis, the eosinophilic phase, in which the main pathological finding
is the eosinophilic organ infiltrations (e.g., lungs, heart, and gastrointestinal system), and
the vasculitic phase, characterized by purpura, peripheral neuropathy, and constitutional
symptoms. ANCA (especially pANCA anti-myeloperoxidase) are present in 40–60% of the
patients. An elevation of IgG4 is frequently found. Corticosteroids and cyclophosphamide
are classically used for remission induction, while azathioprine and methotrexate are the
therapeutic options for remission maintenance. B-cell depletion with rituximab has shown
promising results for remission induction.
Keywords: eosinophilic granulomatosis with polyangiitis, vasculitis, eosinophils, vascular diseases,
ANCA-associated vasculitis
INTRODUCTION AND EPIDEMIOLOGY
Eosinophilic granulomatosis with polyangiitis (EGPA) is a multi-
systemic disorder, belonging to the small vessel anti-neutrophil
cytoplasmic antibody (ANCA)-associated vasculitides (AAVs).
According to the 1994 Chapel Hill consensus conference (CHCC),
EGPA is defined as an eosinophil-rich and granulomatous inflam-
mation often involving the respiratory tract, and necrotizing
vasculitis predominantly affecting small to medium-sized ves-
sels, associated with asthma and eosinophilia. Formerly known as
“Churg–Strauss syndrome,” this eponym has been replaced during
the 2012 Revised International CHCC, with the aim of focusing
on the histopathology of the disease (1). Unlike in the 1990 Ameri-
can College of Rheumatology classification criteria and the former
CHCC, the CHCC 2012 has reported for the first time that ANCA
are found in EGPA, especially in patients with glomerulonephritis.
This reflects some of the newest evidences of the distinction of two
EGPA subsets, depending on the presence or the absence of ANCA
(Table 1) (2).
Eosinophilic granulomatosis with polyangiitis incidence in
Europe is 0.5–6.8 new cases/year per million populations, whereas
its prevalence is 10.7–13 cases per million populations. It mostly
affects subjects between 40 and 60 years old and the mean age at
diagnosis is 48 years (3).
PATHOGENESIS
Eosinophilic granulomatosis with polyangiitis pathogenesis is not
well known. The disease is probably the result of a complex inter-
action in which genetically and environmental factors lead to an
inflammatory response whose principal players are eosinophils, T,
and B lymphocytes (2) (Figure 1).
GENETIC DETERMINANTS
Eosinophilic granulomatosis with polyangiitis is an HLA-
associated disease (4). It has been proven that it is associated
with HLA-DRB1*04 and *07 (5) and with HLA-DRB4 (6). This
contraction of the class II HLA repertoire suggests a strong
CD4+ T lymphocyte activation, possibly triggered by allergens or
antigens.
It has been also investigated the presence of single nucleotide
polymorphisms (SNP) of the gene, which encodes interleukin
(IL)-10, an important molecule for the activation of the Th-2
pathway; EGPA ANCA-negative subset has been associated with
the IL10.2 haplotype of the IL-10 promoter gene, a condition,
which leads to an increased production of IL-10 (7). This is appar-
ently in line with EGPA pathogenesis, which is characterized by
an increased Th-2 response and an increase in IgG4 levels, both of
which seem to be mediated by IL-10.
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Table 1 | Diagnostic criteria, classification, and nomenclature of eosinophilic granulomatosis with polyangiitis during the last 20 years.
Lanham diagnostic criteria
(1984)a
American College of Rheumatology
classification criteria (1990)b
Revised International Chapel Hill consensus
conference nomenclature of vasculitides (2012)
Asthma Asthma Eosinophil-rich and necrotizing granulomatous inflammation often involving
the respiratory tract, and necrotizing vasculitis predominantly affecting
small to medium vessel, and associated with asthma and eosinophilia.
ANCA is more frequent when glomerulonephritis is present.
Eosinophilia (>10% of total WBC)
Blood eosinophilia >1500/mm3
or >10% of total WBC
Neuropathy
Pulmonary infiltrates non-fixed
Evidence of vasculitis involving
two or more organs
Paranasal sinus abnormalities
Extravascular eosinophils
aAll three criteria must be met for a diagnosis of EGPA.
bThe presence of four or more of these six criteria yielded a sensitivity of 85% and a specificity of 99.7% for the classification of vasculitis as EGPA.
WBC, white blood cells.
FIGURE 1 | Eosinophilic granulomatosis with polyangiitis pathogenesis.
ACQUIRED DETERMINANTS
Some environmental triggers have been identified: the exposure
to different allergens, infections, vaccinations could trigger the
disease. Drugs may also have a pathogenetic role and, among
these, the leukotriene receptor antagonists are the most frequently
involved more often used as steroid-sparing agents for asthma,
their key role in triggering EGPA is still uncertain (8). More
recently, also the recombinant anti-IgE monoclonal antibody oma-
lizumab used in patient with asthma has been considered as an
EGPA trigger (9–11). According to the most reliable hypotheses,
both LTRA and anti-IgE antibody may be involved in EGPA patho-
genesis simply unmasking the disease, due to the delayed use of
steroids.
A recent review has shown the possible pathogenetic influence
of silica exposure in AAVs, including EGPA (12).
EOSINOPHILS
The role of the eosinophils is still uncertain in EGPA but dif-
ferent studies have demonstrated the cytotoxic (13, 14) and
pro-coagulant (15, 16) properties of this cell type, which may
result in the development of cardiovascular and cerebrovascu-
lar complications in patients with any type of hypereosinophilic
syndromes including EGPA. Although they are usually considered
to be effector cells, they may act as immunoregulatory cells (2):
indeed, a cross-talk between T-lymphocytes and eosinophils has
been pointed out. In a recent study, high concentrations of IL-
25 have been detected in the sera of EGPA patients; eosinophils
are the main source of IL-25, which induces T-cells to produce
cytokines that stimulate Th-2 and, at the same time, eosinophilic
responses (17).
T-LYMPHOCYTES
It has been demonstrated that T-lymphocytes have an important
role in the EGPA pathogenesis. T-cells are present in the most of
the organ lesions and in some of them, like peripheral neuropa-
thy, they represent the main component. Moreover, serum levels
of T-cell activation markers, like IL-2r, are increased during the
active phase of the disease (18). T-cells receptors show a restricted
repertoire suggesting oligoclonal expansion (19), which is in line
with the hypothesis of an antigen-driven disease. Clonal restricted
effector CD8+ lymphocytes with a proinflammatory profile have
been recently described in patients with EGPA (20).
Specifically, EGPA is considered as a disease with a prevalent
activation of the Th-2 pathway. In keeping with this view, it has
been demonstrated that tissue infiltrates in patients with EGPA
are rich in T-cells with Th-2 makers such as CD294. Furthermore,
EGPA patients CD4+ T-cells are able to produce, in vitro, high
concentrations of IL-4, IL-5, and IL-13, molecules that hallmark
the Th-2 immunoresponse.
High-blood concentrations of IL-17 have been found in
patients with EGPA, a finding, which suggests that the involvement
of Th17 lymphocytes into EGPA pathogenesis; indeed, these lym-
phocytes are involved in the pathogenesis of other autoimmune
diseases (2).
Finally, reduced levels of regulatory CD4+ T-cells (Tregs) have
been discovered in EGPA patients (21, 22). Tregs usually have a
protective role toward the development of autoimmune diseases.
Lower numbers of Tregs were found in active EGPA patients than
in patients with asthma or with chronic eosinophilic pneumonia;
additionally, the percentages of circulating Tregs were lower in
active than quiescent EGPA (2).
B-LYMPHOCYTES
The role of the humoral immunity in EGPA seems to be less
relevant as compared to other autoimmune diseases. Despite this,
EGPA patients often show an abnormal humoral response. ANCA
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are found in about 40% of patients with EGPA, they are character-
ized by a perinuclear pattern (pANCA) at the immunofluorescence
assay and are directed against the neutrophil myeloperoxidase
(MPO), as revealed by ELISA. Their pathogenetic role and their
potential harmful effect is still matter of debate. Even though ani-
mal models and in vitro studies have shown a pathogenic role of
the anti-MPO antibodies (23), their role in causing organ damage
in EGPA is still unknown.
A substantial number of patients show an increased IgG4
blood levels. In a recent analysis of 46 EGPA patients, IgG4 lev-
els correlated with the number of disease manifestations and the
Birmingham vasculitis activity score (BVAS). Furthermore, serum
IgG4 levels paralleled the disease course as they normalized during
remission. The skewed IgG4 response is likely due to the enhancing
effects of the Th-2 cytokines IL-4, IL-5, and IL-13 (24).
CYTOKINES AND CHEMOKINES
Regarding chemotaxis, eotaxin-3 (CCL26), a chemokine, which
attracts eosinophils in the sites of inflammation, apparently has a
key role into EGPA pathogenesis. Two different studies reported
that eotaxin-3 was highly elevated in serum samples of active EGPA
patients and correlated highly significantly with eosinophil counts,
total immunoglobulin E (IgE) levels, and acute-phase parame-
ters. Immunohistochemical analysis revealed strong expression of
eotaxin-3 in endothelial and inflammatory cells in affected tissues
of active EGPA patients (25, 26).
Also, CCL17, another Th-2 chemokine, seems to be present into
both tissues infiltrates and patients’ sera (27).
Some recent studies have demonstrated that EGPA patients’
T-cells produce, after stimulation in vitro, a large amount of
interferon-γ (INF-γ), a cytokine, which boosts Th-1 immune
response (28).
The hypothesis of a cross-talk between humoral and cell-
mediated immunity and eosinophils is still the object of different
pathogenetic studies.
CLINICAL FEATURES
Eosinophilic granulomatosis with polyangiitis mainly affects
patients with asthma (often developed in the adult age), sinusitis,
allergic rhinitis, and nasal polyposis (Table 2) (29).
Eosinophilic granulomatosis with polyangiitis typically devel-
ops into three sequential phases, marked by a progression of the
main symptoms. The first phase, also called prodromic or aller-
gic, is most common in the second or third decade and it is
distinguished by the occurrence of asthma, allergic rhinitis, and
sinusitis. Subsequently, the eosinophilic phase develops the main
pathological findings of this phase are the raise in the peripheral
eosinophilic count and the eosinophilic organ infiltrations, espe-
cially in lungs, heart, and gastrointestinal system. The third phase is
the vasculitic one during this last phase, the patient suffers from the
consequences of a necrotizing vasculitis (e.g., purpura, peripheral
neuropathy), generally associated with vascular or extravascular
granulomatosis and constitutional symptoms like fever, malaise,
and weight loss (35).
Eosinophilic granulomatosis with polyangiitis is a multisys-
temic disease. One of the most frequently involved sites is the
respiratory system asthma has a prevalence of about 95% (36).
Pulmonary eosinophilic infiltrates may be present and their biopsy
is often highly informative for the histopathologic diagnosis (37).
The otorhinolaryngoiatric system is also frequently involved
nasal polyposis is one of the conditions, which lead patients
to undergo repeat surgery. Allergic rhinosinusitis, epistaxis, and
neurosensory hearing loss are other common features (32).
Cardiac involvement may be represents the most harmful man-
ifestation of EGPA characterized by myocardial infarction, peri-
carditis, or congestive heart failure, it is the main cause of death
(30, 36, 38).
Among the most frequent skin manifestations, subcutaneous
nodules, and purpura (especially involving the legs) represent a
clinical hallmark of the vasculitic phase, a skin biopsy of purpuric
lesions generally shows a leukocytoclasic vasculitis (39, 40).
Table 2 | Main clinical features in eosinophilic granulomatosis with polyangiitis and their prevalences.
Clinical features Prevalence (%) Reference
Mean age at diagnosis (years) 50±16 Comarmond et al. (30)
Asthma 91–100 Comarmond et al. (30); Sablé-Fourtassou et al. (31)
Ear, nose, and throat involvement 48–75 Comarmond et al. (30); Bacciu et al. (32)
Neuropathy 55–72 Comarmond et al. (30); Sablé-Fourtassou et al. (31)
Pulmonary involvement 65–91 Sablé-Fourtassou et al. (31); Comarmond et al. (30)
Cutaneous involvement 40–52 Comarmond et al. (30); Sablé-Fourtassou et al. (31)
Renal involvement 27 Sinico et al. (33)
Cardiac involvement 27–35 Comarmond et al. (30); Sablé-Fourtassou et al. (31)
Gastrointestinal involvement 23–32 Comarmond et al. (30); Sablé-Fourtassou et al. (31)
Central nervous system involvement 5–9 Comarmond et al. (30); Sablé-Fourtassou et al. (31)
ANCA positivity 38 Sinico et al. (34)
pANCA positivity 74 of all ANCA+ patients Sinico et al. (34)
ANCA, anti-neutrophil cytoplasmic antibody.
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Although less frequent than the other two AAVs, renal involve-
ment occurs in about 25% of the patients and the most typical
expression is pauci-immune crescentic glomerulonephritis with a
high range of clinical features, from isolated urinary abnormalities
(proteinuria, hematuria) to rapidly progressive glomerulonephri-
tis. Kidney involvement is a bad prognosis factor for patients with
EGPA (33).
Peripheral neuropathy, either sensory or motor or sensory-
motor, affects a large portion of the patients; mononeuritis mul-
tiplex, with axonal damage, usually unilateral and asymmetric, is
the most characteristic manifestation of peripheral nervous system
involvement. Patients report paresthesia and pain in the affected
areas (peroneal, tibial, ulnar nerve), especially during the vasculitic
stage of the disease (41).
In the gastrointestinal system, the vasculitic phase may be pre-
ceded by an eosinophilic gastroenteritis with abdominal pain,
diarrhea, and intestinal bleeding (42).
In the 30–40% of the patient, there can be diffuse lym-
phadenopathy, frequently affecting axillary and cervical lymph
nodes (43).
The most frequent laboratory findings in EGPA patients
is marked hypereosinophilia, frequently between 5000 and
9000 eosinophils/µL [at least >1500 eosinophils/µL or >10% of
the total white blood cells, according to Lanham criteria (44)],
this is one of the most common signs of EGPA (36). An increase
in non-specific inflammatory markers (ESR, CRP) is often found
(36). The role of the complement is still uncertain. ANCA are
present approximately in 40–60% of the patients; pANCA (perin-
uclear) is the prevalent pattern, with antibody specificity for MPO
(33, 34, 45).
All these clinical manifestations and laboratory features could
be frequently gathered into two patterns: the vasculitic and
ANCA-positive phenotype,characterized by manifestations result-
ing from small and medium-sized vessel vasculitis (e.g., purpura,
mononeuritis multiplex, glomerulonephritis) and the eosinophilic,
ANCA-negative phenotype, in which the organ is damaged mainly
by an eosinophilic infiltration (e.g., pulmonary infiltrates, car-
diomyopathy) (2). These findings may have pathogenetic implica-
tions, as they suggest that ANCA, as observed in MPO-ANCA
mouse models, mediate vasculitis in EGPA as well; however,
there are no animal models of EGPA. In addition, the ANCA-
positive and ANCA-negative subsets are not clearly separated, as
overlapping manifestations occur very frequently.
HISTOPATHOLOGY
The main histological findings in EGPA are the extravascular
granulomas, small and medium-sized vessels vasculitis, and the
eosinophilic infiltrates.
Interstitial and vascular granulomas are composed by
eosinophilic necrotic matrix surrounded by giant cells and pal-
isading lymphocytes. The vasculitic process affects mainly small
and medium vessels (especially small arteries) and is character-
ized by fibrinoid necrosis of the vessel wall associated or not with
granuloma or eosinophilic infiltrates (46, 47). It is difficult to find
all these features together, which makes the histological diagnosis
sometimes challenging (48). In addition, specific disease manifes-
tations often show specific histopathological features; for example,
purpura is caused by a leucocytoclastic vasculitis (eosinophilic
infiltration or fibrinoid necrosis is frequently absent) and alveolar
hemorrhage depends on an alveolar capillaritis (without granu-
loma) (36). Furthermore, glomerulonephritis (33) and peripheral
neuropathy frequently lack eosinophilic infiltrates. Gastrointesti-
nal biopsies reveal eosinophilic tissue infiltration and histological
signs of mesenteric vessel vasculitis, which may induce bowel
ischemia (42).
Cardiac involvement may show coronary vasculitis, myocardial
granuloma, eosinophilic endomyocarditis, and pericarditis (36).
DIFFERENTIAL DIAGNOSIS
Different conditions have to be considered in the differential
diagnosis, mainly eosinophilic and vasculitic diseases.
Parasitic infections as well as hypersensitivity reactions (e.g., to
drugs) must be excluded. The hypereosinophilic syndrome (HES)
is characterized by persistent eosinophilia and organ involve-
ment without a reason, which can explain hypeosinophilia. Car-
diac and pulmonary manifestations are analog to those of EGPA
patients but subjects with HES usually do not have asthma or
vasculitic complication like purpura or glomerulonephritis; fur-
thermore, ANCA are absent in HES (49). A recent revised classi-
fication of HESs has focused on the pathogenesis of many hyper-
eosinophilic disorders: myeloproliferative and lymphocytic forms
of HES should be excluded in all patients. Particularly, Fip1-like-
1(FIP1L1)/platelet-derived growth factor receptor α (PDGFRA)
fusion genes must be investigated (50).
Broncho-pulmonary allergic aspergillosis may mimic pul-
monary involvement in EGPA: differential diagnosis is helped
by finding Aspergillus spp at bronchoscopy lavage or dosing
Aspergillus fumigatus specific serum IgE, which are pathogno-
monic of allergic aspergillosis (51).
Acute eosinophilic pneumonia is featured by pulmonary infil-
trates and bronchoscopy lavage rich in eosinophils but usually
originates as an acute illness with fever and dyspnea, without
peripheral eosinophilia or other organ involvement.
Chronic eosinophilic pneumonia diagnosis is more insidious.
Patients may present with asthma, peripheral eosinophilia, and
constitutional symptoms. The absence of other organ manifesta-
tions and the negativity of ANCA may help to differentiate chronic
eosinophilic pneumonia from EGPA (52).
Eosinophilic granulomatosis with polyangiitis must be distin-
guished from the other AAVs. Granulomatosis with polyangiitis
(GPA) may mimic particular aspects of EGPA, especially in those
patients, which present peripheral eosinophilia, the ANCA speci-
ficity (cANCA PR3-specific, in GPA) and the presence, in GPA, of
pulmonary cavitated nodules associated with nasal crusting and
nasal and paranasal sinuses erosion,allow clinicians to differentiate
the two vasculitides.
Although microscopic polyangiitis (MPA) could be also charac-
terized by pANCA with MPO specificity, it rarely shows peripheral
eosinophilia, nodules, or eosinophilic pulmonary infiltrates (48).
Finally, EGPA must be differentiated from IgG4-related disease
(IgG4-RD), which may present with allergic manifestations, blood
eosinophilia, pulmonary infiltrates, and sinusitis. However, tissue
biopsies in patients with IgG4-RD show fibrosis and obliterative
phlebitis, without vasculitis or eosinophilic granulomas (53).
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In our center experience, first level examinations include blood
tests and, in particular, complete blood cell count, ESR, CRP,
immunoglobulins with their subclasses (especially IgG subclasses),
rheumatoid factor, ANCA, eosinophil cationic protein (ECP),
serum B12 levels (elevated in myeloproliferative neoplasms),
and a screening of renal function and urinalysis. Detection of
FIP1L1/PDGFRA fusion genes and stool cultures for ova and
parasite examination must be done in the early stages of diag-
nosis. ANCA are thought to be useful in the differential diagnosis
between EGPA and other (especially infectious and hematologi-
cal) eosinophilic disorders. Likewise, finding fusion genes clearly
points toward a diagnosis of myeloproliferative HES. The differen-
tial diagnosis with lymphocytic forms of HES is more challenging,
as most laboratories do not perform clonal analysis of circulat-
ing lymphocyte subsets or their intracellular cytokine production,
which could be helpful in these conditions.
Second level examinations include imaging studies such as
lung and facial computed tomography (CT), as well as functional
studies such as electromyography.
Finally, kidney biopsy and a bronchoscopy with bronchoalve-
olar lavage are reserved for those patients with severe (and often
rapidly progressive) clinical manifestations.
TREATMENT AND OUTCOME
Eosinophilic granulomatosis with polyangiitis treatment is a mat-
ter of debate because of the lack of large-scale, randomized con-
trolled trials. The five factors score (FFS) may be a guide for
clinicians, this score assigns one point to each of the follow-
ing items, namely, gastrointestinal involvement, CNS involvement,
cardiac involvement, proteinuria >1 g/24 h and serum creatinine
>141µmol/L (35). Patients with poor prognosis factors (FFS
≥1) are often treated with both glucocorticoids (classically pred-
nisone at dosage of 1 mg/kg of total body weight/day with a
maximum dosage of 75 mg/day, for 1 month and then tapered)
and cyclophosphamide (CYC, 2 mg/kg of total body weight/day),
while the typical approach for patients with a better prognosis
(e.g., FFS of 0) is glucocorticoid therapy alone (54). Recently,
a revised FFS has been proposed an age over 65 years, car-
diac symptoms, gastrointestinal involvement, renal insufficiency
(serum creatinine >150µmol/L) and absence of ear, nose, and
throat manifestations have been pointed out as predictors of 5-year
mortality (55).
Classically, used therapies in EGPA remission maintenance are
azathioprine or methotrexate (56).
Although primarily used for GPA, the BVAS, a clinical index
of disease activity (57), might be useful to better decide when to
stop therapy with CYC and introduce maintenance therapy like
azathioprine or methotrexate.
Cyclophosphamide toxicity has long been known (58) and,
based on our center experience, we recommend not to exceed
the dose of 10–15 g of CYC (including both oral and pulse
medications). On the other hand, too-short duration of CYC
administration has been associated with more relapses (59).
Azathioprine too requires a constant monitoring of liver
function, due to the drug-related hepatotoxicity (60).
B-cell depletion adjunct therapy with rituximab has shown
promising results for remission induction (61–67).
Interleukin-5, a major survival factor for eosinophils, has been
targeted in patients with EGPA using the monoclonal antibody
mepolizumab. Use of mepolizumab in refractory cases (68, 69)
and steroid-dependent patients (70) has given positive results but
EGPA manifestations recurred on drug cessation.
On the assumption of its inhibitory effects on the eosinophil
degranulation, interferon-alpha therapy has been tried with pos-
itive results in refractory patients, but the severe drug-related
toxicity has greatly limited its use (71, 72).
Plasmapheresis may be an adjunctive therapy particularly in
patients with rapidly progressive glomerulonephritis, peripheral
neuropathy, or alveolar hemorrhage (2).
Eosinophilic granulomatosis with polyangiitis outcomes are
well represented in a retrospective study of 383 EGPA patients
in the French Vasculitis Study Group cohort. Vasculitis relapse
occurred in 97 patients (25.3%), while 72 additional patients expe-
rienced asthma flares, sinusitis, and/or increased eosinophilia. Of
the 383 patients, 45 (11.7%) died and the major cause of death was
attributed to cardiac events. Five-year and 10-year survival rates
were, respectively, 88.9 and 78.6%. Vasculitis relapse-free survival
rate at 5 years was 64.8%, while at 10 years was 54.4%. ANCA
positivity and cutaneous signs were independent predictors of
relapse (30).
Another recent analysis of EGPA patients’ long-term follow
up has demonstrated that the outcome of EGPA is good with
respect to mortality. According to the analysis of 118 patients with
EGPA (enrolled in two prospective trials), 108 (91.5%) patients
achieved remission (34 of the 108 achieved long-term remission
without relapse) and 12 (10.2%) died (only 5 of them died for
EGPA-related causes). During relapses, pulmonary symptoms pre-
dominated (81%), followed by ear nose and throat signs (38%) and
mononeuritis multiplex (36%) (73).
Finally, in a German cohort of 150 EGPA patients, the analy-
sis of the follow-up of 104 of them has evidenced that 70
patients (67.3%) attained remission after conventional therapies,
21 (14%) suffered from major relapses and 42 (28%) from minor
relapses. Twelve patients died 94± 16 (mean± SD) months after
diagnosis (74).
PERSPECTIVE FUTURE
Despite the great levels of knowledge reached, more has to be
done to clarify EGPA pathogenesis, a genome-wide association
study (GWAS) will probably help to better understand the genetic
determinants of the disease. Besides, the environmental factors
like silica or any other occupational exposure (e.g., asbestos) must
be studied in depth.
In the future, probably, the distinction between ANCA+ and
ANCA− small vessels vasculitides will lead to re-define the current
classification criteria with a more simplistic view of all the AAVs.
Despite this, clinicians should keep in mind all the distinctive
clinical features and differential diagnosis approaches that make
EGPA one of the more characteristic and complex AAV.
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